Aevisbio Inc. and the Korea Research Institute of Chemical Technology have jointly developed new compounds targeting protein cereblon (CRBN) reported to be useful for the treatment of cancer.

Aliad Biopharma Co. Ltd. has described compounds acting as autophagy inducers and mTOR complex 2 (mTORC2) inhibitors reported to be useful for the treatment of Alzheimer’s disease, among others.

Avelos Therapeutics Inc. has divulged DNA polymerase θ (POLθ) inhibitors reported to be useful for the treatment of cancer.

Beijing Konruns Pharmaceutical Co. Ltd. has identified histone acetyltransferase KAT6A (monocytic leukemia zinc finger protein; MOZ; MYST-3) inhibitors reported to be useful for the treatment of cancer.

Beigene Switzerland GmbH has synthesized protein arginine N-methyltransferase 5 (PRMT5) inhibitors reported to be useful for the treatment of cancer.

Micot (Suzhou) Technology Co. Ltd. has disclosed xanthine derivatives reported to be useful for the treatment of hypertension and asthma.

Humanwell Healthcare (Group) Co. Ltd. has patented compounds acting a type-2 angiotensin II receptor (AGTR2; AT2) antagonists reported to be useful for the treatment of neuropathy and neuropathic pain.

Aposense Ltd. has prepared and tested peptide-drug conjugates comprising a cell-penetrating peptide covalently bound to the therapeutically affective amino acid sequence (SAPK1 [JNK] inhibitors) linked to sterol derivatives through a linker reported to be useful for the treatment of cancer.

Nippon Chemiphar Co. Ltd. has disclosed morphinan derivatives acting as κ-opioid receptor agonists reported to be useful for the treatment of cough, pain, pruritus, substance abuse and dependence, and liver, respiratory, neurological and cardiovascular disorders.

Eli Lilly & Co. has synthesized GTPase KRAS and its G12 mutant inhibitors reported to be useful for the treatment of cancer.